Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* COPD patients having at least one exacerbation within last year~* FEV1/FVC ratio (post-bronchodilator) ≤ 70%~* FEV1 (post-bronchodilator) ≤ 50% of predicted~Main Exclusion Criteria:~* COPD exacerbation not resolved at first baseline visit~* Diagnosis of asthma and/or other relevant lung disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): 500 mcg, once daily, oral administration in the morning
- Placebo (Type: PLACEBO_COMPARATOR): once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).